After a post-earnings (I, II) meeting with management, Jefferies isn't too concerned about the recent Medicare/ Medicaid "setback" for Cyberonics' (CYBX +0.5%) VNS Therapy (previous). "The addressable market" could be expanded to include new indications like congestive heart failure analyst Raj Denhoy says, and besides, CYBX "is firing on all cylinders in epilepsy." Ultimately, "strong, sustainable growth" equals a reiterated Buy rating (PT $60).
After a post-earnings (I, II) meeting with management, Jefferies isn't too concerned about the...
From other sites
at CNBC.com (Jan 5, 2015)
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 2, 2014)
at CNBC.com (Aug 28, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs